Inclusion criteria
Histologically confirmed grade 3 glioma; measurable progressive disease by contrast-enhanced MRI after standard therapy; WHO performance status (PS) of 0-2; more than 4 weeks from chemotherapy; more than 3 months from completion of radiation therapy. 1
Response evaluation RANO criteria.
Immunohistochemistry
Extent of staining was semiquantitatively evaluated. Cut-points were prespecified according to published litterature.
Statistical analysis
Comparison of group medians were performed using the MannWhitney U method and tests for independence between categorical variables were done by Fisher's exact test. Factors were screened by univariate analysis using logistic regression and Cox regression modelling response and survival endpoints. Screened factors with a p-value < 5 % were considered for multivariate analysis. The association between objective response and survival at 9 weeks was evaluated using the landmark method. 
Conclusions
• Poor PS and necrosis were negatively associated with response
• Poor PS and response to prior CTX were prognostic of reduced PFS
• Poor PS and high p53 expression were prognostic of reduced OS
• Objective response is an early efficacy endpoint for bevacizumab
